Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
about
Adjuvant chemotherapy for resected early-stage non-small cell lung cancerExploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responsesRole of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new dataTargeted therapy for localized non-small-cell lung cancer: a reviewPost-operative radiation therapySystemic and targeted therapies for early-stage lung cancer2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerResearch Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer50 Years of progress in the systemic therapy of non-small cell lung cancerPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung CancerCancer nanomedicine: from targeted delivery to combination therapyTrial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocolThe Lake Wobegon effect: are all cancer patients above average?Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancerHow individual participant data meta-analyses have influenced trial design, conduct, and analysisPredicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung SignatureLung cancer in Brazil: epidemiology and treatment challenges.Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.Prognostic gene signatures for non-small-cell lung cancer.Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerPostoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.BRCA1: a novel prognostic factor in resected non-small-cell lung cancerVinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinaseAdjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataRandomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.Prognostic factors in resected lung carcinomas.
P2860
Q24187439-A43EF473-7088-459C-8E58-1BF73786EF9EQ24604495-3133EB76-4D72-4E5F-80CB-B0E07D0E5871Q24633254-7A65FA49-125B-491C-8CFE-D617A8D195DEQ26741441-F3BE05E5-4AC9-4B59-81AD-905E04C79A62Q26830376-BEC84D58-5F8D-4B8E-8033-06B504E983BFQ26865490-6FBA4381-2A7E-4C56-9D4D-C72DDBB43DB4Q27002509-92E95862-0F68-42F7-A940-09FDBCF1BD51Q27006349-A982C452-719C-4587-BA73-63C82A01D210Q27014978-085DA4E5-78FD-42D3-ACC2-CEEE44DE5F01Q27313799-3B55D2D4-961E-47A8-91FE-088F424CDD9DQ28080636-42CA5DF0-D899-4303-A773-239B7B6C3921Q28083065-81C6AD1B-1C88-4C28-B1A9-A9D855E3F65EQ28209997-34B9ED1A-7DB3-4B32-8288-16611FF49595Q28303620-51AA57DF-195E-4681-B152-50C498311442Q28394974-B098FEBF-99A2-401E-87EB-593D5A847EBBQ28607751-71D6C4A4-E3F6-4F1B-A39E-3F75340352F9Q28608174-FD8C9B36-00A8-4B5E-BB31-F38EE97D0E7DQ30235908-1687512D-671A-447D-AD6E-A6078598B95CQ30249083-59971CCE-CC46-421F-B34A-B7BA7431DF11Q30358684-B5D94F45-FDBA-4A2D-A0F8-55526D3E5624Q30430515-58747330-6EEA-4168-B7A5-ECF43195C512Q30438068-53E35BD9-7E55-46E6-BFCF-ED2C44A159A0Q30485836-561DF306-5760-45C0-BE08-90495A292623Q30487077-3AF56813-FDC5-420C-93E6-6E63369C6A2DQ30498101-C9288A30-C441-41ED-BD88-01A5FD8D3DD4Q30539299-0ED9D6FB-6B8B-49D6-9E28-784927E6A574Q30868582-205AB68C-88D7-4BB0-B4D5-570E24E300E2Q30976026-DB541E6B-8F8D-4589-9FF7-A159DC720752Q30993385-A555FE66-2770-4C67-AE44-68A400C94C0EQ33305206-F7524F76-7454-40F6-B063-DF117A0A2DE1Q33375704-DAEA679B-B6E3-4F94-960A-1A1D1960B7E0Q33404434-910D61C4-B2AE-400F-9DA9-F090A7080983Q33408830-6A83F2C6-A262-49F3-AB59-BF508F0044F7Q33429178-F957B6D7-D812-4862-BA38-CA491A6E5FF4Q33437409-7A642F26-BFD3-4175-B084-4B042FF683EBQ33521840-867B9654-EA96-4A78-BBEF-DFA69402270CQ33546241-BA51E2C4-563F-4416-AF34-F965E5A9C87DQ33561943-B97C9737-C766-4F95-B614-68F7BE85C089Q33684103-D5A4D8F2-4242-44E0-8273-19EF8D4A2C54Q33697964-5E1BDC5E-0B9B-4CAF-849A-1C8C837C73C3
P2860
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@ast
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@en
type
label
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@ast
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@en
prefLabel
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@ast
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@en
P2093
P50
P1433
P1476
Adjuvant vinorelbine plus cisp ...... a randomised controlled trial.
@en
P2093
Alain Le Groumellec
Angel Artal-Cortes
Antonio J Torres
Claude Clary
Francesco Carpagnano
Jabrail Dahabreh
Jose Luis Gonzáles-Larriba
Jose Rodrigues Pereira
Julio Astudillo
Leona Koubkova
P304
P356
10.1016/S1470-2045(06)70804-X
P577
2006-09-01T00:00:00Z